Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

Inclusion Criteria: * Informed consent form has been signed and dated * Able to attend all scheduled visits and comply with all trial procedures. * Never received rabies vaccine before. * Refrain from blood donation during the course of the study. * Able to attend all scheduled visits and comply with all trial procedures. Exclusion Criteria: * For women who are pregnant and breast-feeding * Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccine or another vaccine * History of allergies to the medicine (S), convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction * Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth * Participation in any other interventional clinical trial * Donation of blood within the last 2 months or who have donated plasma within the last 14 days * Patient with clinical signs of encephalitis * Recipient of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination * Planned participation in another clinical trial during the present trial period * Concomitant use or at high probability of expected concomitant use during the planned study of medication such as immune suppressants, steroids, non-study vaccine or similar substances * Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Administration of immunoglobulins and/or any blood products within 3 months prior to the first dose of study vaccine or planned administration during the study period. * History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * Uncontrolled acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history or physical examination. * Chronic administration of immuno-suppressants or other immune-modifying drugs within 3 months prior to the first vaccine dose. * Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor